In an analysis of the DISCOVER-2 trial, guselkumab treatment reduced impairment in work productivity and improved general health status in PsA over 2 years.
The STRIDE study did not meet its primary or secondary efficacy endpoint The company to suspend mavodelpar development and implement a workforce reduction IRVINE, Calif., Dec. 14, 2023 Reneo.
Reneo Pharmaceuticals Announces Results from Pivotal STRIDE globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.